A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
- Conditions
- Leukemia, Acute Myeloid (AML)
- Interventions
- Drug: LoDAC (Low Dose Cytarabine)Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)Drug: FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 371
- Registration Number
- NCT02421939
- Locations
- 🇺🇸
Site US10011, Birmingham, Alabama, United States
🇺🇸Site US10012, Los Angeles, California, United States
🇺🇸Site US10076, Orange, California, United States
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02383368
- Locations
- 🇺🇸
Site US10001, New Haven, Connecticut, United States
🇺🇸Site US10004, Chicago, Illinois, United States
🇺🇸Site US10002, Rochester, Minnesota, United States
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
- Conditions
- Castration-resistant Prostate CancerProstate CancerMetastatic Prostate Cancer
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1030
- Registration Number
- NCT02380274
- Locations
- 🇺🇸
Site USSUB1007, Homewood, Alabama, United States
🇺🇸Site USSUB1010, Anchorage, Alaska, United States
🇺🇸Site USSUB1111, Phoenix, Arizona, United States
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
- Conditions
- Painful Diabetic Peripheral Neuropathy (PDPN)
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT02372578
- Locations
- 🇺🇸
Site US10001, Anniston, Alabama, United States
🇺🇸Site US10039, Phoenix, Arizona, United States
🇺🇸Site US10054, Fresno, California, United States
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02236013
- Locations
- 🇺🇸
Site US10003, Los Angeles, California, United States
🇺🇸Site US10013, New Haven, Connecticut, United States
🇺🇸Site US10004, Chicago, Illinois, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 888
- Registration Number
- NCT02216214
- Locations
- 🇺🇸
Site US00066, Huntsville, Alabama, United States
🇺🇸Site US00148, Mobile, Alabama, United States
🇺🇸Site US00009, Anchorage, Alaska, United States
A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662
- Conditions
- Pharmacokinetics of ASP3662Healthy VolunteersDisplacement of Radiotracer
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02194491
- Locations
- 🇺🇸
Site US10001, New Haven, Connecticut, United States
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
- Conditions
- Relapsed Lymphoid MalignancyRefractory Lymphoid Malignancy
- Interventions
- Drug: AGS67E
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02175433
- Locations
- 🇺🇸
Site US0006, Duarte, California, United States
🇺🇸Site US0002, Stanford, California, United States
🇺🇸Site US0004, Fairway, Kansas, United States
A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate
- Conditions
- Pharmacokinetics of ASP2409Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT02171143
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸West Coast Clinical Trials, LLC, Costa Mesa, California, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections
- Conditions
- Pharmacokinetics of ASP2408Healthy Subjects
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02150070
- Locations
- 🇺🇸
Parexel International, Baltimore, Maryland, United States